X0202 SCHEDULE 13G/A 0001172661-25-004834 0001856083 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value per share 03/31/2026 0001819790 Tarsus Pharmaceuticals, Inc. 87650L103 15440 Laguna Canyon Road Suite 160 Irvine CA 92618 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 3600000.00 0.00 3600000.00 3600000.00 N 8.46 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 3600000.00 0.00 3600000.00 3600000.00 N 8.46 CO David Kroin b X1 0.00 3600000.00 0.00 3600000.00 3600000.00 N 8.46 HC IN Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160, Irvine, California, 92618 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 3,600,000 8.46% 0 3,600,000 0 3,600,000 Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of March 31, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 42,557,492 Common Stock outstanding as of February 17, 2026, according to the issuer's 10-K filed with the SEC on February 23, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP /s/ David Kroin 05/15/2026 Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin 05/15/2026 David Kroin /s/ David Kroin 05/15/2026